X
<

Where Is Novartis Positioned after 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Where Is Novartis Positioned after 3Q17? PART 1 OF 12

How Did Novartis Perform in 3Q17?

Novartis revenue trends

In 3Q17, Novartis (NVS) reported revenues of ~$12.4 billion, which was ~2% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

In 3Q17, Novartis reported operating income of $2.36 billion, compared with $2.27 billion in 3Q16. In 3Q17, Novartis reported net income of ~$2.1 billion, compared with $1.9 billion in 3Q16. In 3Q17, the company reported basic EPS (earnings per share) of $0.89, compared with $0.81 in 3Q16. In 3Q17, Novartis reported free cash flow of $3.06 billion, compared with $2.59 billion in 3Q16.

How Did Novartis Perform in 3Q17?

Interested in NVS? Don't miss the next report.

Receive e-mail alerts for new research on NVS

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

From January 2017 to September 2017, Novartis generated revenues of ~$36.2 billion. Novartis Cosentyx, Entresto, Promacta, and Tafinlar-Mekinist primarily attributed to this revenue growth during the first nine months of 2017.

Recent developments

In October 2017, Novartis (NVS) submitted a supplemental Biologics License Application (or sBLA) to the FDA (US Food and Drug Administration) for Kymriah for the treatment of adult individuals with relapsed or refractory DLBCL (diffuse large B-cell lymphoma) who are not eligible for autologous stem cell transplant (or ASCT).

In April 2017, the FDA established a Breakthrough Therapy designation for Kymriah for the treatment of individuals with DLBCL. Novartis’s sBLA submission to the FDA was based on the phase-2 Juliet trial, which evaluated the safety and efficacy of Kymriah exclusively for DLBCL.

Previously, Kymriah had received FDA approval for the treatment of individuals under 25 years of age with B-cell precursor acute lymphoblastic leukemia (or ALL) that has relapsed at least twice.

By comparison, Pfizer (PFE), Merck (MRK), Bristol-Myers Squibb (BMY), and Roche reported revenues of ~$13.2 billion, ~$10.3 billion, ~$5.3 billion, and ~26.3 billion Swiss francs, respectively. The Vanguard FTSE Developed Markets ETF (VEA) has ~0.78% of its total portfolio holdings in NVS.

X

Please select a profession that best describes you: